These findings indicate that IFNα2b could be used as an easily performed, first-line treatment, with the potential to yield complete tumor resolution or significant reduction in tumor size in a case that may have otherwise required complicated eyelid reconstruction or enucleation. The gene discussed is IFNA2; the disease is neoplasm.